The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
Authors
Keywords
-
Journal
OncoImmunology
Volume 7, Issue 4, Pages e1414119
Publisher
Informa UK Limited
Online
2017-12-19
DOI
10.1080/2162402x.2017.1414119
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
- (2016) E. Picarda et al. CLINICAL CANCER RESEARCH
- The immune mechanisms of abscopal effect in radiation therapy
- (2016) G. Daniel Grass et al. CURRENT PROBLEMS IN CANCER
- Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes
- (2016) Amalie Kai Bentzen et al. NATURE BIOTECHNOLOGY
- Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
- (2016) Lewis Zhichang Shi et al. Nature Communications
- Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking?
- (2016) Sandra Demaria et al. Journal for ImmunoTherapy of Cancer
- Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study
- (2015) Riccardo Danielli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model
- (2015) Nicolle H. Rekers et al. RADIOTHERAPY AND ONCOLOGY
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- PD-1 Restrains Radiotherapy-Induced Abscopal Effect
- (2015) S. S. Park et al. Cancer Immunology Research
- A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab
- (2015) Ravi A Chandra et al. OncoImmunology
- Role of Local Radiation Therapy in Cancer Immunotherapy
- (2015) Sandra Demaria et al. JAMA Oncology
- Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
- (2015) C. M. L. Zegers et al. CLINICAL CANCER RESEARCH
- Armed antibodies for cancer treatment: a promising tool in a changing era
- (2014) Riccardo Danielli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
- (2014) S. J. Dovedi et al. CANCER RESEARCH
- An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA
- (2014) Marco Demaria et al. DEVELOPMENTAL CELL
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses
- (2014) B. Weide et al. Cancer Immunology Research
- Combinations of Immunotherapy and Radiation in Cancer Therapy
- (2014) Ralph E. Vatner et al. Frontiers in Oncology
- Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
- (2013) Silvia C. Formenti et al. JNCI-Journal of the National Cancer Institute
- Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
- (2013) Paul F Robbins et al. NATURE MEDICINE
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma
- (2013) Laura M. Alwan et al. Targeted Oncology
- The Immunocytokine L19–IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF
- (2012) Kathrin Schwager et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Radiation as an immunological adjuvant: current evidence on dose and fractionation
- (2012) Sandra Demaria et al. Frontiers in Oncology
- Radiation-induced effects and the immune system in cancer
- (2012) Punit Kaur et al. Frontiers in Oncology
- A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
- (2011) T. K. Eigentler et al. CLINICAL CANCER RESEARCH
- Maximizing Tumor Immunity With Fractionated Radiation
- (2011) Dörthe Schaue et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
- (2010) Manfred Johannsen et al. EUROPEAN JOURNAL OF CANCER
- Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment
- (2009) Y. Lee et al. BLOOD
- Radiofrequency Ablation Combined with KS-IL2 Immunocytokine (EMD 273066) Results in an Enhanced Antitumor Effect against Murine Colon Adenocarcinoma
- (2009) E. E. Johnson et al. CLINICAL CANCER RESEARCH
- Systemic effects of local radiotherapy
- (2009) Silvia C Formenti et al. LANCET ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started